Figure 6.

Validation of RPL23AP53 expression levels using data from Gene Expression Omnibus (GEO). A. Differences in expression in normal, benign nevi, and malignant melanoma samples based on GSE3189, One way Anova with Dunn’s multiple comparisons test; B. Expression in epidermal keratinocytes and melanocytes compared to metastatic melanoma cell lines (GSE3189), only one replicates included in data set per sample type; C. Expression levels based on primary tumor and metastatic samples from GSE8401, Mann Whitney test; D. Comparison of normal (normal skin, benign nevi, atypical nevi) and cancer (melanoma in situ, vertical and metastatic growth phases, lymph node metastasis) samples in GDS1989 data set, dots represent mean of value, only two replicates available per sample type; dashed lines in violin plots represent mean of expression; p < 0.05 considered as significant; ns — non significant, **p ≤ 0.01, ***p ≤ 0.001